CA2950211C - 3-((piperazin-1-yl)methyl)-phenyl amide derivatives and their use as retinoid-related orphan receptor gamma (ror.gamma.) modulators - Google Patents
3-((piperazin-1-yl)methyl)-phenyl amide derivatives and their use as retinoid-related orphan receptor gamma (ror.gamma.) modulators Download PDFInfo
- Publication number
- CA2950211C CA2950211C CA2950211A CA2950211A CA2950211C CA 2950211 C CA2950211 C CA 2950211C CA 2950211 A CA2950211 A CA 2950211A CA 2950211 A CA2950211 A CA 2950211A CA 2950211 C CA2950211 C CA 2950211C
- Authority
- CA
- Canada
- Prior art keywords
- methyl
- methylpiperazin
- chloro
- substituted
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Transplantation (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2014000540 | 2014-05-28 | ||
| CNPCT/CN2014/000540 | 2014-05-28 | ||
| PCT/CN2015/079753 WO2015180612A1 (en) | 2014-05-28 | 2015-05-26 | Novel compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2950211A1 CA2950211A1 (en) | 2015-12-03 |
| CA2950211C true CA2950211C (en) | 2023-02-07 |
Family
ID=54698093
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2950211A Active CA2950211C (en) | 2014-05-28 | 2015-05-26 | 3-((piperazin-1-yl)methyl)-phenyl amide derivatives and their use as retinoid-related orphan receptor gamma (ror.gamma.) modulators |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US9902735B2 (OSRAM) |
| EP (1) | EP3148975B1 (OSRAM) |
| JP (1) | JP6759110B2 (OSRAM) |
| KR (1) | KR20170012389A (OSRAM) |
| CN (1) | CN106536489B (OSRAM) |
| AU (1) | AU2015267909B2 (OSRAM) |
| BR (1) | BR112016027732B1 (OSRAM) |
| CA (1) | CA2950211C (OSRAM) |
| ES (1) | ES2710487T3 (OSRAM) |
| MX (1) | MX378098B (OSRAM) |
| RU (1) | RU2016150535A (OSRAM) |
| WO (1) | WO2015180612A1 (OSRAM) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105121430B (zh) | 2012-12-06 | 2017-06-16 | 葛兰素集团有限公司 | 用于治疗自身免疫性和炎性疾病的类维生素A相关的孤儿受体γ(RORγ)的调节剂 |
| US9868724B2 (en) | 2014-05-28 | 2018-01-16 | Glaxosmithkline Intellectual Property Development Limited | Compounds |
| KR20170012388A (ko) | 2014-05-28 | 2017-02-02 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | 신규 화합물 |
| EP3474942B1 (en) * | 2016-06-23 | 2023-07-19 | Kessler Foundation Inc. | Testosterone replacement therapy in combination with neuromuscular stimulation |
| MY196990A (en) | 2016-07-13 | 2023-05-17 | Leo Pharma As | Heteroaromatic modulators of the retinoid-related orphan receptor gamma |
| MX2019007213A (es) | 2016-12-21 | 2019-08-16 | Jiangsu Hengrui Medicine Co | Derivado de azaciclobutil triazol del grupo anular condensado, metodo de preparacion del mismo y uso del mismo en medicina. |
| CA3047641A1 (en) | 2016-12-28 | 2018-07-05 | Jiangsu Hengrui Medicine Co., Ltd. | Azabicyclo-substituted triazole derivative, preparation method thereof, and application of same in medicine |
| CN109134476B (zh) * | 2017-06-15 | 2021-03-19 | 复旦大学 | 桥环哌嗪类衍生物或其盐及其制备方法和用途 |
| JPWO2019022223A1 (ja) * | 2017-07-28 | 2020-06-11 | 東レ株式会社 | 環状アミン誘導体及びその医薬用途 |
| CN107698462A (zh) * | 2017-10-10 | 2018-02-16 | 重庆科脉生物化工有限公司 | 一种1‑氨基‑1‑环丙腈盐酸盐的制备方法 |
| CN109438423A (zh) * | 2018-09-12 | 2019-03-08 | 通化师范学院 | 一种肺癌靶向化合物azd-3759的合成工艺的新方法 |
| JPWO2021177431A1 (OSRAM) * | 2020-03-06 | 2021-09-10 | ||
| CN116234548A (zh) * | 2020-06-09 | 2023-06-06 | 再生治疗有限公司 | 作为pd-1/pd-l1阻断剂的包含三环母核的化合物 |
| CN116239445B (zh) * | 2023-01-05 | 2024-10-18 | 万华化学集团股份有限公司 | 一种丙内酯开环加氢合成1,3-丙二醇的方法 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU714931B2 (en) * | 1995-12-18 | 2000-01-13 | Fujisawa Pharmaceutical Co., Ltd. | Piperazine derivatives as tachykinin antagonists |
| US7790726B2 (en) | 2005-08-16 | 2010-09-07 | Chemocentryx, Inc. | Monocyclic and bicyclic compounds and methods of use |
| US7825120B2 (en) | 2005-12-15 | 2010-11-02 | Cytokinetics, Inc. | Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas |
| US20070208000A1 (en) | 2005-12-15 | 2007-09-06 | Morgan Bradley P | Certain chemical entities, compositions and methods |
| JP5178526B2 (ja) * | 2005-12-19 | 2013-04-10 | サイトキネティクス・インコーポレーテッド | 化合物、組成物および方法 |
| WO2012028100A1 (en) | 2010-09-01 | 2012-03-08 | Glaxo Group Limited | Novel compounds |
| WO2012027965A1 (en) | 2010-09-01 | 2012-03-08 | Glaxo Group Limited | Novel compounds |
| WO2012100734A1 (en) | 2011-01-24 | 2012-08-02 | Glaxo Group Limited | Compounds useful as retinoid-related orphan receptor gamma modulators |
| WO2012100732A1 (en) | 2011-01-24 | 2012-08-02 | Glaxo Group Limited | Retinoid-related orphan receptor gamma modulators, composition containing them and uses thereof |
| EP2511263A1 (en) * | 2011-04-14 | 2012-10-17 | Phenex Pharmaceuticals AG | Pyrrolo sulfonamide compounds for modulation of orphan nuclear receptor RAR-related orphan receptor-gamma (RORgamma, NR1F3) activity and for the treatment of chronic inflammatory and autoimmune diseases |
| WO2012145254A2 (en) | 2011-04-16 | 2012-10-26 | Board Of Regents, The University Of Texas System | Methods of using inhibitors of rorϒt to treat disease |
| CA2833493C (en) | 2011-04-28 | 2020-06-02 | Japan Tobacco Inc. | Amide compound and pharmaceutical application therefor |
| US9586928B2 (en) * | 2011-05-16 | 2017-03-07 | The Scripps Research Institute | Modulators of the nuclear hormone receptor ROR |
| KR20140072090A (ko) | 2011-09-09 | 2014-06-12 | 뉴욕 유니버시티 | ＲＯＲγｔ 조정제로서의 아미도 화합물 및 이의 용도 |
| GB201116641D0 (en) | 2011-09-27 | 2011-11-09 | Glaxo Group Ltd | Novel compounds |
| MX2014012989A (es) | 2012-04-27 | 2015-01-22 | Glaxo Group Ltd | Compuestos novedosos. |
| GB201207406D0 (en) | 2012-04-27 | 2012-06-13 | Glaxo Group Ltd | Novel compounds |
| CN105121430B (zh) * | 2012-12-06 | 2017-06-16 | 葛兰素集团有限公司 | 用于治疗自身免疫性和炎性疾病的类维生素A相关的孤儿受体γ(RORγ)的调节剂 |
| WO2013171729A2 (en) | 2013-01-08 | 2013-11-21 | Glenmark Pharmaceuticals S.A. | Aryl and heteroaryl amide compounds as rorgamat modulator |
| US10286000B2 (en) | 2013-10-25 | 2019-05-14 | St. Jude Children's Research Hospital, Inc. | Retinoid X receptor-gamma agonists and retinoid X receptor-alpha antagonists for treatment of cancer |
| WO2015061515A1 (en) | 2013-10-25 | 2015-04-30 | Glaxosmithkline Llc | Novel compounds |
| KR20170012388A (ko) | 2014-05-28 | 2017-02-02 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | 신규 화합물 |
| US9868724B2 (en) | 2014-05-28 | 2018-01-16 | Glaxosmithkline Intellectual Property Development Limited | Compounds |
-
2015
- 2015-05-26 MX MX2016015630A patent/MX378098B/es unknown
- 2015-05-26 CA CA2950211A patent/CA2950211C/en active Active
- 2015-05-26 JP JP2016569766A patent/JP6759110B2/ja active Active
- 2015-05-26 EP EP15800398.8A patent/EP3148975B1/en active Active
- 2015-05-26 BR BR112016027732-5A patent/BR112016027732B1/pt active IP Right Grant
- 2015-05-26 CN CN201580039564.9A patent/CN106536489B/zh active Active
- 2015-05-26 KR KR1020167036017A patent/KR20170012389A/ko not_active Withdrawn
- 2015-05-26 AU AU2015267909A patent/AU2015267909B2/en not_active Ceased
- 2015-05-26 WO PCT/CN2015/079753 patent/WO2015180612A1/en not_active Ceased
- 2015-05-26 ES ES15800398T patent/ES2710487T3/es active Active
- 2015-05-26 RU RU2016150535A patent/RU2016150535A/ru not_active Application Discontinuation
- 2015-05-26 US US15/314,111 patent/US9902735B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| MX378098B (es) | 2025-03-10 |
| EP3148975A4 (en) | 2018-01-03 |
| RU2016150535A (ru) | 2018-07-03 |
| CA2950211A1 (en) | 2015-12-03 |
| CN106536489A (zh) | 2017-03-22 |
| KR20170012389A (ko) | 2017-02-02 |
| BR112016027732A2 (OSRAM) | 2017-08-15 |
| BR112016027732B1 (pt) | 2023-11-07 |
| WO2015180612A1 (en) | 2015-12-03 |
| EP3148975A1 (en) | 2017-04-05 |
| EP3148975B1 (en) | 2018-11-28 |
| US9902735B2 (en) | 2018-02-27 |
| CN106536489B (zh) | 2020-02-07 |
| ES2710487T3 (es) | 2019-04-25 |
| JP6759110B2 (ja) | 2020-09-23 |
| US20170197978A1 (en) | 2017-07-13 |
| AU2015267909A1 (en) | 2016-12-01 |
| AU2015267909B2 (en) | 2018-03-22 |
| MX2016015630A (es) | 2017-04-25 |
| RU2016150535A3 (OSRAM) | 2018-12-26 |
| JP2017516796A (ja) | 2017-06-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2950211C (en) | 3-((piperazin-1-yl)methyl)-phenyl amide derivatives and their use as retinoid-related orphan receptor gamma (ror.gamma.) modulators | |
| EP3468960B1 (en) | Chemical compounds as atf4 pathway inhibitors | |
| AU2022275504A1 (en) | Pyrimidinyl tyrosine kinase inhibitors | |
| WO2018225093A1 (en) | Chemical compounds as atf4 pathway inhibitors | |
| MX2011005800A (es) | Derivados de n{[(1r,4s,6r)-3-(2-piridinilcarbonil)-3-azabiciclo[4. 1.0]hept-4-il]metil}-2-heteroarilamina y sus usos. | |
| KR20160106622A (ko) | 화합물 | |
| US9902715B2 (en) | Compounds | |
| EP3148987B1 (en) | Piperazine derivatives as ror-gamma modulators | |
| CA3066328A1 (en) | Chemical compounds as atf4 pathway inhibitors | |
| KR20180050408A (ko) | 국부 약물 전달용의 비스테로이드성 글루코코르티코이드 수용체 조절제 | |
| BR112016027749B1 (pt) | Composto modulador do receptor órfão relacionado à retinóide gama (rory), composição farmacêutica compreendendo dito composto e uso do mesmo para o tratamento de esclerose múltipla e espondilite anquilosante |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20200519 |
|
| EEER | Examination request |
Effective date: 20200519 |
|
| EEER | Examination request |
Effective date: 20200519 |
|
| EEER | Examination request |
Effective date: 20200519 |
|
| EEER | Examination request |
Effective date: 20200519 |
|
| EEER | Examination request |
Effective date: 20200519 |